The proportion of CD45 + cells in the tumor and blood identified as NKT cells were also greatest in the combination treatment group (0.71% and 0.18%, respectively) and were significantly increased compared to untreated (p < 0.001) and vehicle controls (p < 0.05) and in the case of blood also significantly greater compared to the anti-mCTLA-4-treated group (p < 0.05) (Online Resource Figure S4a-b). Here, PTPRC is linked to neoplasm.